MBX Biosciences (MBX) Receivables - Other (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Receivables - Other data on file, last reported at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 127.94% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 127.94% YoY), and the FY2025 full-year result was $2.1 million, up 210.85% from the prior year.
• Receivables - Other climbed to $3.2 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $3.2 million in Q1 2026 to a low of $208000.0 in Q4 2023.
• A 4-year average of $1.3 million and a median of $1.1 million in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other soared 227.88% in 2024 and surged 80.42% in 2025, its largest moves.
• Tracing MBX's Receivables - Other over 4 years: stood at $208000.0 in 2023, then soared by 227.88% to $682000.0 in 2024, then jumped by 210.85% to $2.1 million in 2025, then surged by 48.92% to $3.2 million in 2026.
• Business Quant data shows MBX's Receivables - Other at $3.2 million in Q1 2026, $2.1 million in Q4 2025, and $1.5 million in Q3 2025.